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ABSTRACT
Background: Reports of somatic mutations found in
hearts with cardiac septal defects have suggested that
these mutations are aetiologic in pathologic cardiac
development. However, the hearts in these reports had
been fixed in formalin for over 22 years. Because of the
profound implication of this finding, we attempted to
replicate it using fresh frozen tissue obtained in the
current era from 28 patients with septal defects who
underwent cardiac surgery and who were enrolled in our
congenital heart disease tissue bank.
Methods: Our cohort included patients with atrial septal
defects (ASD, n=13), ventricular septal defects (VSD,
n=5), and atrioventricular canal defects (AVCD, n=10).
Cardiac tissue samples were collected both from diseased
tissue located immediately adjacent to the defect and
from anatomically normal tissue located at a site remote
from the defect (right atrial appendage). Tissue samples
were immediately frozen in liquid nitrogen and stored at
280uC. Genomic DNA was isolated and amplified using
the same methodology described in the previously
published reports. 42 pathologic cardiac tissue samples
were sequenced.
Results: One non-synonymous germline sequence variant
was identified in one patient. Two synonymous germline
sequence variants were identified in two separate
patients. A common single nucleotide polymorphism
(SNP) was identified in 16 patients. Based on the
incidence of somatic mutations described in the
previously published reports, our study was adequately
powered to replicate the previous studies. No evidence of
somatic mutations was found in this study.
Conclusion: Somatic mutations in NKX2-5 do not
represent an important aetiologic pathway in pathologic
cardiac development in patients with cardiac septal
defects.
Congenital heart disease (CHD) is a common
congenital birth defect, affecting nearly 1% of all
live births, and is the most common cause of infant
death from birth defects. The aetiology of CHD in
the majority of cases is unknown. Abnormal
cardiac development appears to occur through a
process that is heterogeneous and complex, with
both environmental and genetic risk factors.
1
The NKX2-5 gene on chromosome 5q34 consists
of two exons which encode a 324 amino acid
protein. This homeobox transcription factor is
expressed during early cardiac morphogenesis and
serves as a master regulatory protein.
2–4 Because of
its critical role in cardiogenesis, NKX2-5 has been a
prime candidate in studies to identify the genetic
basis of structural congenital heart defects.
Mutations have been identified in patients with a
variety of congenital heart malformations includ-
ing septal defects, conotruncal abnormalities,
cardiomyopathy, and hypoplastic left heart syn-
drome.
5–7
Recent reports have suggested a novel genetic
mechanism for CHD. Somatic mutations were
identified in NXK2-5 and its molecular partners,
TBX5 and GATA4, as well as the transcription
factor HEY2 in formalin fixed tissue taken from a
collection of hearts with atrial septal defects
(ASD),
8 ventricular septal defects (VSD), and
atrioventricular canal defects (AVCD).
9–13 Somatic
NKX2-5 sequence variants were found in .95% of
human hearts (66 of 68 hearts had a sequence
variant) with septal defects and were detected by
direct sequencing.
10 13 These sequence variants
were primarily identified within malformed
regions and not in unaffected regions taken from
the same heart, indicating a somatic and mosaic
nature for these variants. The investigators suggest
that somatic sequence variants occur with high
frequency and are aetiologic in cardiac malforma-
tions. Moreover, multiple NKX2-5 sequence var-
iants as well as multiple haplotypes were observed
in a majority of these patients.
10 13 The same
investigators also found somatic sequence variants
in a number of other transcription factors such as
TBX5, GATA4, and HEY2, often simultaneously
within the same patient.
9–13 The observation of two
or more somatic sequence variants in the same
patients and even within the same gene is expected
to be an exceedingly rare event and would suggest
a condition of extreme genetic instability, reminis-
cent of that observed in cancer.
13
The somatic NKX2-5 sequence variants were
identified in DNA extracted from an archive of
formalin fixed tissues that are at least 22 years old,
the University of Leipzig (Germany) collection of
malformed hearts.
91 01 3Because formalin can cause
random base damage and affect polymerase chain
reaction (PCR) fidelity,
14 and degraded DNA or
extremely low quantities of DNA from old frozen
samples can increase risk for poor data quality,
15 we
were interested in replicating these experiments
using fresh frozen cardiac tissue instead of formalin
fixed tissue after decades of storage. We established
a CHD tissue bank that houses blood and surgical
discards from over 200 CHD patients. For this
study, a cohort of 28 patients with both normal
tissue samples and tissue samples within 1 mm of
a septal defect were included. Genomic DNA
(gDNA) was isolated from pathologic cardiac tissue
and non-diseased cardiac tissue and blood collected
from this cohort of CHD patients. gDNA from
cardiac tissue samples was amplified by PCR and
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J Med Genet 2009;46:115–122. doi:10.1136/jmg.2008.060277 115screened for NKX2-5 mutations using direct sequencing and by
a second more sensitive method, temperature gradient capillary
electrophoresis (TGCE),
16 to screen for any low frequency
sequence variants that may not have been detected by direct
sequencing.
PATIENTS AND METHODS
Patients
Institutional review board approval through the University of
Louisville was granted both for the establishment of the CHD
tissue bank and for this study. Written informed consent was
obtained from all patients. Assent was obtained from paediatric
participants when appropriate. Blood and surgical discards for
DNA studies were obtained from the CHD tissue bank. All
samples in this study were obtained from CHD patients
undergoing cardiac surgery at Kosair Children’s Hospital
(Louisville, Kentucky, USA) between March 2005 and March
2006. Tissue samples were obtained from surgical discards at the
time of operation and from one heart explanted at the time of
death (patient 18, table 1). Fourteen were female (50%) and 14
were male (50%). The mean age at time of surgery was 5.8 years
(median 1.6 years, range 0–36.8 years).
The study cohort included 28 unrelated patients with normal
tissue samples and phenotypically abnormal tissue samples
within 1 mm of the rim of ASD,
8 VSD, and AVCD (table 1).
This cohort was selected from the CHD tissue bank because
they represented the same types of cardiac malformations
included in the previous reports.
10–14
Sample size calculation and statistical analysis
Power calculations were performed for a test comparing two
proportions where somatic NKX2-5 sequence variants were
observed in 66 out of 68 patients (n1=68 patients; p1=66/68)
and n2=28 patients from this study. An observation of somatic
variants in fewer than 22 patients would be considered
significantly different from the previously published study
reports (a=0.05, b=0.8).
Sample collection and DNA isolation
Blood samples were acquired at the time of surgery. Tissue
discards were snap frozen in liquid nitrogen and then stored in a
freezer at 280uC. Genomic DNA was isolated from pheno-
typically normal and pathologic cardiac tissue and amplified
using methods described previously.
13 Genomic DNA was
isolated from blood using QIAamp DNA Blood Midi Kit
Protocol (Qiagen, Valencia, California, USA) and from 2–10
mg of frozen cardiac tissue samples using NucleoSpin Tissue Kit
(Clontech Laboratories, Inc, Mountain View, California, USA).
Amplification of NKX2-5 fragments
Previously published primer sequences were used for the
amplification of the NKX2-5 fragments 1A, 1B, 2A, and 2B.
51 7
The coding region of the NKX2-5 gene, including exon/intron
boundaries, was amplified from genomic DNA by PCR. PCR
reactions consisted of 20–30 ng of genomic DNA, 3 ml of PCR
buffer, 6 ml of 5X Q solution (Qiagen), 3 ml of dNTPs, 0.3 mlo f
Hotstar Taq (Qiagen), 1.5 ml (20 pmol/ml) of each primer pair,
to a volume of 30 ml with distilled water. PCR reactions were
undertaken on a Bio-Rad Thermal Cycler (Bio-Rad Laboratories
Hercules, California, USA). Reactions started with 15 min at
95uC, followed by 40 cycles of 45 s at 95uC, 30 s at 60uC, and
45 s at 72uC, and finished with a 10 min extension period at
72uC.
DNA sequencing
Double-stranded DNA fragments obtained from PCR reactions
were purified with the MinElute PCR Purification Kit (Qiagen)
using spin columns in a microcentrifuge. DNA samples were
analysed by double-strand direct sequencing using NKX2-5
specific primers. The sequencing reaction was performed using
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, California, USA). Bidirectional sequen-
cing was performed by an ABI 3730XL automated cycle
sequencer (Applied Biosystems). Sequences were analysed using
the software program, Sequencher v4.5 (Gene Codes Corp, Ann
Arbor, Michigan, USA) as well as proof read by eye. The
numbering of nucleotide changes was based on the reference
sequence NM_002052 with +1 as the adenine nucleotide of the
first codon ATG.
If a nucleotide sequence variation was found in DNA isolated
from a pathologic cardiac tissue sample, then genomic DNA
isolated from blood and/or phenotypically normal cardiac tissue
samples obtained from the same patient was sequenced in an
identical manner. Sequence variations found in genomic DNA
isolated from pathologic cardiac tissue were then compared to
sequencing results obtained from blood samples and normal
heart tissues of the same patient.
TGCE screening
To screen for sequence variants that might exist at frequencies
lower than that expected to be detected by direct sequencing, a
capillary electrophoresis based heteroduplex analysis platform
(TGCE) was used (Spectrumedix System, Transgenomic Inc,
Omaha, Nebraska). gDNA from pathologic cardiac samples and
either blood and/or atrial appendage from all 28 patients was
amplified by PCR and used to create heteroduplexes as
previously described.
16 TGCE analysis was performed on an
automated 96 capillary array instrument (Spectrumedix
System, Transgenomic Inc). DNA samples consisting of
homoduplexes and heteroduplexes were separated by capillary
electrophoresis, during which a thermal ramp from 50uCt o
60uC was applied over 25 min; the injection conditions were
6 kV for 50 s using Reveal matrix (Spectrumedix System,
Transgenomic Inc). SpectruMedix Check Mate Software was
used for instrument control and data acquisition with a data
acquisition time of 65 min. Data were analysed by use of the
SpectruMedix Reveal Mutation Software as well as proof read
by eye. The system generated the electropherograms for our
reference sequence, the wild-type plus mutant (mixed) samples,
and the mutant unmixed samples. Sequence variants were
identified by automated detection of peak patterns where the
presence of two peaks on an electropherogram indicated a
nucleotide change.
RESULTS
A total of 28 patients were selected for this study. They
included: atrial septal defects (ASD=13: 11 isolated secundum
ASD, one sinus venosus ASD with partial anomalous pulmon-
ary venous return, one secundum ASD with total anomalous
pulmonary venous return); ventricular septal defects (VSD=5:
two isolated perimembranous VSD, one perimembranous VSD
with right aortic arch and aberrant left subclavian artery, one
perimembranous VSD with D-transposition of the great vessels,
pulmonary atresia and hypoplastic left ventricle, one malalign-
ment VSD with tetralogy of Fallot); and AV canal defects
(AVCD=10: eight with complete AV canal defects (CAVC),
and two with transitional AV canal defects (TAVC)). Table 1
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118 J Med Genet 2009;46:115–122. doi:10.1136/jmg.2008.060277summarises the cohort of patients and the tissue samples
obtained. Preoperative blood samples were available for 27
operative patients (blood was not available for patient 18).
Right atrial appendage was available as a surgical discard
because its removal was necessary before placing the patients on
cardiopulmonary bypass; tissue samples from the right atrial
appendage were available for 27 patients (atrial appendage was
not available for patient 27). In total, 42 pathologic cardiac
tissue samples were available for study.
NKX2-5 sequence variations
Four single nucleotide changes were identified in 17 patients;
one non-synonymous variation and three synonymous varia-
tions were found in the NKX2-5 coding region (table 2). The
non-synonymous sequence variant (65A.G) was heterozygous
and was identified in one patient with an ASD (fig 1). This
sequence variant results in a glutamine-to-arginine (Q22R)
amino acid substitution, and is located on exon 1, just outside of
the TN domain.
Three separate synonymous sequence variations were found
in 17 patients. The first is a common single nucleotide
polymorphism (SNP), rs2277923 (63 A.G), and was identified
in 17 patients. According to dbSNP, average heterozygosity of
rs2277923 is 0.49¡0.07. Heterozygosity of the CHD population
in this study was 0.46 (13 of 28 patients). Seven of these
patients had ASD (patients 1, 5, 7, 8, 10, 11, and 13), four had
VSD (patients 14, 16, 17, and 18), and six had AVCD (patients
20, 21, 23, 24, 25, and 28). Thirteen of these patients were
heterozygous, and four were homozygous for this variation.
The second synonymous sequence variant, 543G.A, was found
in one patient with a secundum ASD (patient 8). The patient
was heterozygous for this nucleotide change. This patient was
also heterozygous for the 63A.G SNP. The 543G.A variant
has not been previously reported. The third sequence variant,
852 C.G, was found in one patient with a secundum ASD and
total anomalous pulmonary venous return (patient 13). This
patient was also heterozygous for this sequence variant and the
63 A.G SNP. We do not believe the 852C.G variant has been
reported previously.
TGCE results
TGCE results were consistent with the above sequencing
results. No additional peaks representing potential additional
mutations were detected in pathologic or normal cardiac tissues.
The sensitivity of TGCE is better than direct sequencing;
mutations present at 1 in 20 ratios are detected reliably.
16
Comparison with unaffected tissues
To determine if any of the sequence variations identified in
pathologic tissue were germline or somatic, blood samples and
phenotypically normal heart tissues were also screened from the
same patient. We analysed 50 sequence variations discovered in
both normal and pathologic tissues in seven patients with ASD
(patients 1, 5, 7, 8, 10, 11, and 13), four patients with VSD
(patients 14, 16, 17, and 18), and six patients with AVCD
(patients 20, 21, 23, 24, 25, and 28). Every nucleotide sequence
variant found in the pathologic tissue samples was also found in
the normal cardiac tissue or blood samples taken from the same
patient—indicating that these were germline variants. We
found no evidence of NXK2-5 somatic sequence variants in
any of our samples.
DISCUSSION
There is convincing evidence that germline NKX2-5 mutations
are aetiologic in CHD.
5–7 The aim of our current study was to
replicate the previous finding of somatically derived sequence
variants in patients with septal defects.
10 13 In these published
reports, somatic NKX2-5 sequence variants were primarily
identified within malformed regions and were not seen in
unaffected regions of the heart; taken together, these findings
suggest that somatic mutations occur with high frequency and
are also aetiologic in CHD.
10 13
These remarkable reports come from DNA isolated from
archival tissues after more than 22 years of formalin storage.
Formalin is known to create PCR artefacts that may appear as
mutations. The purpose of our study was to replicate these
controversial findings using fresh frozen cardiac tissue instead of
.22-year-old formalin fixed tissue. We sequenced genomic
DNA isolated from pathologic cardiac tissues collected as
surgical discards from patients with CHD and searched for
NKX2-5 mutations. We compared our finding with sequencing
results using DNA from concurrently obtained non-diseased
cardiac tissue and blood samples. We identified three novel
germline NKX2-5 sequence variants in our cohort of 28
unrelated CHD patients. One ASD patient was found to have
a heterozygous sequence variant located just outside of the TN
domain and results in an amino acid substitution. Two unique
silent sequence variants were identified in two patients who
also carried a common SNP. The common SNP was identified in
16 patients. No evidence of somatic NKX2-5 sequence variants
was found in any of the samples described herein.
Table 2 Summary of NKX2-5 mutations in patients with congenital
heart defects
Nucleotide change
Predicted amino
acid change Location
ASD
(+)
VSD
(+)
AVCD
(+)
Non-synonymous
c.65A.G p.Q22R Exon 1 1
Synonymous
c.63A.G Exon 1 6 4 6
c.543G.A Exon 2 1
c.852C.G Exon 2 1
ASD, atrial septal defects; AVCD, atrioventricular canal defect; VSD, ventricular septal
defects.
Figure 1 The NKX2-5 heterozygous sequence variant c.65A.G
(Q22R). The missense change was identified in the forward and reverse
genomic DNA strands isolated from blood (A) and pathologic cardiac
tissue (B) of the same patient. ASD, atrial septal defect.
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was isolated from 5 mg of tissue obtained as surgical discards
that were immediately frozen. In comparison, yields from the
Leipzig collection were reportedly 0.5–1 mg of genomic DNA
from 25 mg DNA obtained from archival tissue. Therefore, the
recovery of gDNA from our fresh frozen samples was more than
five times that of the formalin fixed samples. The relatively poor
gDNA yield from the Leipzig collection likely reflects the poor
quality of DNA taken from samples that had been fixed in
formalin between 22–50 years.
Mutational spectra comparisons
The Human Gene Mutation Database
18 is an up-to-date and
comprehensive collection of published germline mutations in
nuclear genes underlying or associated with human inherited
disease.
19 The database is maintained by the Institute of Medical
Genetics in Cardiff and is available online at www.hgmd.org. It
contains statistics on 34 066 germline single nucleotide sub-
stitutions. Guanine-to-adenine (G.A) mutations dominate the
database. The majority (44%) of single nucleotide substitutions
have been reported to be G.A variations. The second most
prevalent sequence variation is an adenine-to-guanine (A.G)
substitution (17%).
The International Agency for Research on Cancer (IARC)
TP53 Mutation Database is a compilation of all P53 gene
mutations identified in human cancers and cell lines that have
been reported in the peer review literature since 1989.
20 It is
available online at www.iarc.fr/P53/. The R10 release of the
Somatic Mutation Dataset contains 21 587 mutations asso-
ciated with human cancers. Of these, there are 18 643 single
nucleotide substitutions. Again, G.A nucleotide substitutions
comprised the majority (51%) of the reported sequence
variations. Only 13% of the P53 somatic variations were A.G
substitutions.
To date, there are 60 germline NKX2-5 single nucleotide
substitutions that have been published in the peer review
literature.
6 The vast majority (61%) of these are also G.A
substitutions. A.G substitutions have been reported in only 2%
of these sequence variations.
Six hundred and five somatic sequence variants were reported
in the coding and flanking intron regions of NKX2-5.
10 13 When
we analysed the spectrum of these sequence variants, found
after amplification from DNA extracted from formalin fixed
Figure 2 Mutational spectra
comparisons. Guanine-to-adenine
nucleotide substitutions are the most
frequently reported sequence variation in
the germline Human Gene Mutation
Database (HGMD) (A), the International
Agency for Research on Cancer (IARC)
TP53 Somatic Mutation Database (B),
and previously published NKX2-5
germline mutations (C). Adenine-to-
guanine substitutions are the most
common sequence variant reported in
previously published NKX2-5 somatic
mutations (D).
10 13
Figure 3 Mutational spectra of somatic TBX5 mutations. Adenine-to-
guanine nucleotide substitutions are the most common sequence variant
reported in previously published TBX5 somatic mutations.
9
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dominated these studies (58% of these sequence variants were
A.G substitutions) and only 31% were G.A substitutions.
Similarly, the same group found somatic sequence variants in
the TBX5 gene from the same archival collection of hearts. TBX5
encodes a transcription factor that interacts with NKX2-5 and is
important in vertebrate cardiac development.
21 22 One hundred
and thirty-five somatic sequence variations have been reported
by the same authors in the coding and flanking intron regions of
TBX5.
9 Of the single nucleotide substitutions reported, 87%
were adenine-to-guanine substitutions. Only 11% were gua-
nine-to-adenine substitutions.
MITOMAP is a comprehensive database of human mitochon-
drial DNA (mtDNA) variation and its relationship with human
evolution and disease.
23 It is available online at www.
MITOMAP.org. MITOMAP maintains a compendium of all
known pathogenic mtDNA mutations. The MITOMAP
Somatic Mutation database (updated 6 April 2006) contains
135 single base substitution mutations. The MITOMAP Coding
and Control Region Point Mutation database (updated 18 May
2006) contains 277 single base substitution mutations.
Although dominant mutational pathways in the mitochondria
may be quite different from mutational pathways in nuclear
genes, again, G.A nucleotide substitutions comprised the
majority of the reported sequence variations in both the
germline and in somatic mtDNA mutations (46% and 44%,
respectively). A.G substitutions were found in 39% of the
reported germline mutations and 43% of the somatic mutations.
These analyses, summarised in figs 2–4, demonstrate that the
somatic mutational spectra from the Reamon–Buettner studies
are significantly different from germline NKX2-5 mutations as
well as significantly different from inherited disease associated
mutations, tumour derived somatic mutations, and mitochon-
drial mutations. While these differences may reflect true
differences between the patients at the mutational pathway
level (germline versus somatic versus mitochondrial mutations),
geographic and/or patient level (Germany and/or CHD patients
versus an international collections of cancer databases), or the
temporal level (over 22 years ago versus the current era), it is
also possible that the previously reported somatic variants reflect
postmortem artefacts of fixation or low quality DNA template.
Recent studies also show that lower starting yield of genomic
DNA from archival samples can result in higher misincorporation
rates during PCR in a sequence dependent manner.
24
Much work needs to be done to define the genetic basis of
CHD. The complex relationship between environmental stres-
ses, genetic mutations and elaborate molecular mechanisms
which lead to structural heart defects remain to be elucidated.
We were unable to replicate the previously published findings of
somatically derived sequence variants when fresh frozen cardiac
tissue was used instead of .22-year-old formalin fixed tissues.
We identified novel germline NKX2-5 sequence variants in our
CHD cohort, but we found no evidence of somatic variants
using direct sequencing. More sensitive mutation detection
approaches may be necessary to see low frequency somatic
variants. However, the somatic mutation data from the
previously published studies were obtained by conventional
sequencing. We have shown that our recovery of genomic DNA
from fresh frozen samples was five times greater than the gDNA
recovery from that study which used formalin fixed samples.
Furthermore, we have shown that the somatic NKX2-5
mutational spectrum from the previous study is quite different
from other germline and somatic mutation databases. We hope
this work both elevates the discussion regarding somatic
mutations and the aetiology of CHD and challenges the
interpretation of genetic data obtained from formalin fixed
archival tissues.
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Figure 4 Mutational spectra of
mitochondrial mutations. Guanine-to-
adenine nucleotide substitutions are the
most frequently reported sequence
variation in germline mitochondrial DNA
(A) and somatic mitochondrial DNA (B).
Key points
c Somatic mutations in NKX 2.5 were not found in any fresh
frozen diseased tissue sample from 28 patients with cardiac
septal defects.
c Somatic mutations in NKX 2.5 are not a major aetiological
pathway in cardiac septal defect formation.
c Low yield or poor template DNA quality may account for the
apparent observations of somatic mutations in previously
published reports.
c Mutational spectra are an important consideration in somatic
mutation analysis.
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